Oliver Gaemperli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Oliver Gaemperli has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Philipp A. Kaufmann
Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, CH-8091 Zurich, Switzerland
14 shared publications- Dominik C. Benz
Department of Nuclear Medicine, Cardiac Imaging, University Hospital of Zurich, Ramistrasse 100, CH-8091, Zurich, Switzerland; Advanced Clinician Scientist Program, University Medicine Zurich (UMZH), Switzerland; Department of Cardiology, University Hospital of Zurich, Ramistrasse 100, CH-8091, Zurich, Switzerland
7 shared publications - Philipp A. Kaufmann
Department of Nuclear Medicine, Cardiac Imaging, University Hospital of Zurich, Ramistrasse 100, CH-8091, Zurich, Switzerland
7 shared publications Thomas F. Lüscher
University Hospital Zürich
7 shared publicationsHatem Alkadhi
University Hospital Zürich
6 shared publicationsInes Valenta
Department of Medical Radiology and Cardiovascular Center, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland
6 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 71 (5) , 382-390
Técnicas de imagen híbridas en cardiopatía isquémica
- 1 May 2018
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 71 (5) , 382-390
Técnicas de imagen híbridas en cardiopatía isquémica
- Open Access
- 14 February 2018
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 19 (8) , 838-846
Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials
It is unclear whether non-invasive screening of asymptomatic diabetic patients for coronary artery disease (CAD) may improve cardiac outcomes. Thus, we performed a systematic literature review and meta-analysis of randomised controlled trials (RCT’s) on this topic. We searched appropriate RCT’s in five online databases (PubMed/MEDLINE, Cochrane Library, Embase, Scopus, and Web of Science) from January 2000 to November 2017 and in 41 recent reviews. Two investigators independently extracted and assessed study data using standardised forms. Additional unpublished data were obtained from trial authors. The primary endpoint ‘any cardiac event’ was a composite of cardiac death, non-fatal myocardial infarction (MI), unstable angina (UA), or heart failure (HF) hospitalisation. We performed a meta-analysis of relative risks (RRs) with 95% confidence intervals (CI) using the Mantel–Haenszel method. We included five RCT’s with 3299 patients, of which 189 (5.7%) experienced any cardiac event on follow-up (weighted mean 4.1 years). Non-invasive CAD screening significantly reduced any cardiac event by 27% [RR 0.73 (95% CI 0.55–0.97), P = 0.028, number needed to screen 56]. This result was driven by important, albeit non-significant decreases in non-fatal MI [RR 0.65 (95% CI 0.41–1.02), P = 0.062] and HF hospitalisation [RR 0.61 (95% CI 0.33–1.10), P = 0.100]. Non-invasive CAD screening did not significantly affect cardiac death [RR 0.92 (95% CI 0.53–1.60), P = 0.77] and UA [RR 0.73 (95% CI 0.41–1.31), P = 0.29]. Compared with the standard care, non-invasive CAD screening reduced cardiac events by 27% in asymptomatic diabetic patients, largely through reductions in non-fatal MIs, and HF hospitalisations. The present results justify larger, appropriately powered trials to potentially revisit current recommendations.
- 14 February 2018
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 19 (8) , 838-846
Open AccessNon-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials
It is unclear whether non-invasive screening of asymptomatic diabetic patients for coronary artery disease (CAD) may improve cardiac outcomes. Thus, we performed a systematic literature review and meta-analysis of randomised controlled trials (RCT’s) on this topic. We searched appropriate RCT’s in five online databases (PubMed/MEDLINE, Cochrane Library, Embase, Scopus, and Web of Science) from January 2000 to November 2017 and in 41 recent reviews. Two investigators independently extracted and assessed study data using standardised forms. Additional unpublished data were obtained from trial authors. The primary endpoint ‘any cardiac event’ was a composite of cardiac death, non-fatal myocardial infarction (MI), unstable angina (UA), or heart failure (HF) hospitalisation. We performed a meta-analysis of relative risks (RRs) with 95% confidence intervals (CI) using the Mantel–Haenszel method. We included five RCT’s with 3299 patients, of which 189 (5.7%) experienced any cardiac event on follow-up (weighted mean 4.1 years). Non-invasive CAD screening significantly reduced any cardiac event by 27% [RR 0.73 (95% CI 0.55–0.97), P = 0.028, number needed to screen 56]. This result was driven by important, albeit non-significant decreases in non-fatal MI [RR 0.65 (95% CI 0.41–1.02), P = 0.062] and HF hospitalisation [RR 0.61 (95% CI 0.33–1.10), P = 0.100]. Non-invasive CAD screening did not significantly affect cardiac death [RR 0.92 (95% CI 0.53–1.60), P = 0.77] and UA [RR 0.73 (95% CI 0.41–1.31), P = 0.29]. Compared with the standard care, non-invasive CAD screening reduced cardiac events by 27% in asymptomatic diabetic patients, largely through reductions in non-fatal MIs, and HF hospitalisations. The present results justify larger, appropriately powered trials to potentially revisit current recommendations.
- Open Access
- 25 December 2017
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 31 (2) , 251-260
Percutaneous pulmonary valve implantation in grown‐up congenital heart disease patients: Insights from the Zurich experience
Objectives: The aim of the study was to assess indications, procedural success, complications, echocardiographic, and clinical outcomes of percutaneous pulmonary valve implantation (PPVI) in adult patients with congenital heart disease (CHD).Background: PPVI offers a non‐surgical treatment option for failing prosthetic conduits in pulmonary position. However, efficacy and clinical outcomes after PPVI are still underreported.Methods: From January 2008 to March 2016, 25 adult CHD patients with right ventricular outflow tract (RVOT) stenosis and/or pulmonary regurgitation underwent PPVI in our institution. Clinical and echocardiographic data was collected at baseline, at 12 months of follow‐up and yearly afterwards.Results: Tetralogy of Fallot and repaired pulmonary atresia were among the most prevalent underlying congenital defects. Twenty‐one (84%) received a Medtronic Melody® and four (16%) patients an Edwards Sapien valve prosthesis. The PPVI procedure was successful in all 25 patients. Pre‐stenting was performed in all but two (8%) patients. PPVI reduced peak‐to‐peak pulmonary valve gradient from 43 (IQR 28‐60) mmHg to 16 (IQR 14‐22) mmHg (P < 0.001). Periprocedural complications occurred in two (8%) patients (tricuspid valve damage, pulmonary artery perforation). Over a median follow‐up of 43 (IQR 18‐58) months all patients were alive. Only two (8%) required re‐operation and two (8%) developed stent fractures (one of them had not undergone pre‐stenting). NYHA functional class improved significantly, with 20 (80%) patients in NYHA class I on follow‐up.Conclusions: PPVI with Medtronic Melody or Edwards Sapien valve conduits is safe and provides effective relief from right ventricular outflow tract obstruction or pulmonary regurgitation.
- 25 December 2017
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 31 (2) , 251-260
Open AccessPercutaneous pulmonary valve implantation in grown‐up congenital heart disease patients: Insights from the Zurich experience
Objectives: The aim of the study was to assess indications, procedural success, complications, echocardiographic, and clinical outcomes of percutaneous pulmonary valve implantation (PPVI) in adult patients with congenital heart disease (CHD).Background: PPVI offers a non‐surgical treatment option for failing prosthetic conduits in pulmonary position. However, efficacy and clinical outcomes after PPVI are still underreported.Methods: From January 2008 to March 2016, 25 adult CHD patients with right ventricular outflow tract (RVOT) stenosis and/or pulmonary regurgitation underwent PPVI in our institution. Clinical and echocardiographic data was collected at baseline, at 12 months of follow‐up and yearly afterwards.Results: Tetralogy of Fallot and repaired pulmonary atresia were among the most prevalent underlying congenital defects. Twenty‐one (84%) received a Medtronic Melody® and four (16%) patients an Edwards Sapien valve prosthesis. The PPVI procedure was successful in all 25 patients. Pre‐stenting was performed in all but two (8%) patients. PPVI reduced peak‐to‐peak pulmonary valve gradient from 43 (IQR 28‐60) mmHg to 16 (IQR 14‐22) mmHg (P < 0.001). Periprocedural complications occurred in two (8%) patients (tricuspid valve damage, pulmonary artery perforation). Over a median follow‐up of 43 (IQR 18‐58) months all patients were alive. Only two (8%) required re‐operation and two (8%) developed stent fractures (one of them had not undergone pre‐stenting). NYHA functional class improved significantly, with 20 (80%) patients in NYHA class I on follow‐up.Conclusions: PPVI with Medtronic Melody or Edwards Sapien valve conduits is safe and provides effective relief from right ventricular outflow tract obstruction or pulmonary regurgitation.
- 12 December 2017
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 25 (2) , 521-525
Are the differences clinically relevant? The European Perspective
- 12 December 2017
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 25 (2) , 521-525
Are the differences clinically relevant? The European Perspective
- Open Access
- 25 November 2017
- Published by Springer Nature in EJNMMI Research
- Vol. 7 (1) , 92
Diagnostic accuracy of coronary opacification derived from coronary computed tomography angiography to detect ischemia: first validation versus single-photon emission computed tomography
Estimation of functional relevance of a coronary stenosis by fractional flow reserve (FFR) from coronary computed tomography angiography (CCTA) has recently provided encouraging results. Due to its limited availability, the corrected contrast opacification (CCO) decrease and the transluminal attenuation gradient (TAG) were suggested as less complex alternatives. The aim of the present study was to assess the accuracy of CCO decrease and TAG to predict ischemia as assessed by single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). This retrospective study included 72 patients who underwent hybrid CCTA/SPECT MPI with at least one coronary artery stenosis. Of 127 vessels with a coronary stenosis in CCTA, 38 (30%) were causing ischemia in its subtending myocardium. The area under the curve (AUC) for CCO decrease to predict ischemia was 0.707 with sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of 74, 64, 85, 47, and 67%, respectively. For TAG, the AUC was 0.469. CCTA-derived CCO decrease but not TAG predicts ischemia in SPECT MPI. The negative predictive value of CCO decrease of 85% may confer clinical implications in the diagnostic work-up of patients with a coronary stenosis.
- 25 November 2017
- Published by Springer Nature in EJNMMI Research
- Vol. 7 (1) , 92
Open AccessDiagnostic accuracy of coronary opacification derived from coronary computed tomography angiography to detect ischemia: first validation versus single-photon emission computed tomography
Estimation of functional relevance of a coronary stenosis by fractional flow reserve (FFR) from coronary computed tomography angiography (CCTA) has recently provided encouraging results. Due to its limited availability, the corrected contrast opacification (CCO) decrease and the transluminal attenuation gradient (TAG) were suggested as less complex alternatives. The aim of the present study was to assess the accuracy of CCO decrease and TAG to predict ischemia as assessed by single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). This retrospective study included 72 patients who underwent hybrid CCTA/SPECT MPI with at least one coronary artery stenosis. Of 127 vessels with a coronary stenosis in CCTA, 38 (30%) were causing ischemia in its subtending myocardium. The area under the curve (AUC) for CCO decrease to predict ischemia was 0.707 with sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of 74, 64, 85, 47, and 67%, respectively. For TAG, the AUC was 0.469. CCTA-derived CCO decrease but not TAG predicts ischemia in SPECT MPI. The negative predictive value of CCO decrease of 85% may confer clinical implications in the diagnostic work-up of patients with a coronary stenosis.
- 1 November 2017
- Published by Springer Nature
- p. 1837-1849
Historical Account Cardiology
- 1 August 2017
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 24 (4) , 1302-1304
The right timing for post-ischemic stunning
- 1 August 2017
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 24 (4) , 1302-1304
The right timing for post-ischemic stunning
- 1 June 2017
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 90 (1074) , 20160933
A low-dose and an ultra-low-dose contrast agent protocol for coronary CT angiography in a clinical setting: quantitative and qualitative comparison to a standard dose protocol
Objective:To evaluate the impact of a low-dose (LD) and an ultra-LD (ULD) contrast protocol for coronary CT angiography on qualitative and quantitative image parameters in a clinical setting.Methods:We scanned 120 consecutive patients with a 256-slice CT scanner applying a LD (60 patients, 35–55 ml) or ULD (60 patients, 25–45 ml) contrast protocol adapted to the body mass index. Visually assessed image quality and attenuation measured in each coronary segment were retrospectively compared in 20 consecutive patients scanned with a normal-dose (ND, 40–105 ml) contrast protocol.Results:Visually assessed image quality did not differ significantly among protocols. By contrast, attenuation obtained from the ULD protocol (median contrast volume 35 ml) differed significantly from the LD (median 45 ml) and ND (median 70 ml) protocols in the coronary segments (316 ± 52 vs 363 ± 60 and 359 ± 52 HU, p < 0.001). Attenuation did not differ significantly between the LD and ND protocol. The proportion of patients with in...
- 1 June 2017
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 90 (1074) , 20160933
A low-dose and an ultra-low-dose contrast agent protocol for coronary CT angiography in a clinical setting: quantitative and qualitative comparison to a standard dose protocol
Objective:To evaluate the impact of a low-dose (LD) and an ultra-LD (ULD) contrast protocol for coronary CT angiography on qualitative and quantitative image parameters in a clinical setting.Methods:We scanned 120 consecutive patients with a 256-slice CT scanner applying a LD (60 patients, 35–55 ml) or ULD (60 patients, 25–45 ml) contrast protocol adapted to the body mass index. Visually assessed image quality and attenuation measured in each coronary segment were retrospectively compared in 20 consecutive patients scanned with a normal-dose (ND, 40–105 ml) contrast protocol.Results:Visually assessed image quality did not differ significantly among protocols. By contrast, attenuation obtained from the ULD protocol (median contrast volume 35 ml) differed significantly from the LD (median 45 ml) and ND (median 70 ml) protocols in the coronary segments (316 ± 52 vs 363 ± 60 and 359 ± 52 HU, p < 0.001). Attenuation did not differ significantly between the LD and ND protocol. The proportion of patients with in...
- Open Access
- 12 August 2016
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 23 (4) , 384-392
Changes in serum biomarker profiles after percutaneous mitral valve repair with the MitraClip system
Mitral regurgitation (MR) is one of the most common valvular diseases. Percu-taneous mitral valve repair with the MitraClipTM system is a novel percutaneous mitral valve repair (PMVR) technique for high-surgical-risk patients. However, the effect of PMVR on cir-culating cardiac or inflammatory biomarkers and their association with individual functional, echocardiographic and clinical outcomes is poorly investigated. A group of 144 patients with functional or degenerative MR (age, 75 ± 11 years; 41% females) underwent PMVR with the MitraClip system at the University Heart Center Zu-rich. Serum biomarkers as N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP) and creatinine were obtained from venous sampling at baseline and follow-up of 3-6 months. Median NT-proBNP decreased insignificantly from 2,942 (IQR 1,596-5,722) to 2,739 (IQR 1,440-4,296) ng/L, p = 0.21. NT-proBNP changes did not correlate with baseline left ventricular (LV) ejection fraction or LV dimensions, with New York Heart Association class on follow-up, or with clinical events on follow-up. CRP levels reached a peak on the third postoperative day at 34.0 mg/L with a subsequent slow decrease over the ensuing days. Despite successful PMVR, NT-proBNP remain fairly unchanged on follow-up and changes in NT-proBNP levels are poor predictors of functional improvement or clinical outcome after MitraClip treatment.
- 12 August 2016
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 23 (4) , 384-392
Open AccessChanges in serum biomarker profiles after percutaneous mitral valve repair with the MitraClip system
Mitral regurgitation (MR) is one of the most common valvular diseases. Percu-taneous mitral valve repair with the MitraClipTM system is a novel percutaneous mitral valve repair (PMVR) technique for high-surgical-risk patients. However, the effect of PMVR on cir-culating cardiac or inflammatory biomarkers and their association with individual functional, echocardiographic and clinical outcomes is poorly investigated. A group of 144 patients with functional or degenerative MR (age, 75 ± 11 years; 41% females) underwent PMVR with the MitraClip system at the University Heart Center Zu-rich. Serum biomarkers as N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP) and creatinine were obtained from venous sampling at baseline and follow-up of 3-6 months. Median NT-proBNP decreased insignificantly from 2,942 (IQR 1,596-5,722) to 2,739 (IQR 1,440-4,296) ng/L, p = 0.21. NT-proBNP changes did not correlate with baseline left ventricular (LV) ejection fraction or LV dimensions, with New York Heart Association class on follow-up, or with clinical events on follow-up. CRP levels reached a peak on the third postoperative day at 34.0 mg/L with a subsequent slow decrease over the ensuing days. Despite successful PMVR, NT-proBNP remain fairly unchanged on follow-up and changes in NT-proBNP levels are poor predictors of functional improvement or clinical outcome after MitraClip treatment.